Download Files:
Aurintricarboxylic acid
$55 – $61
Products Details
Product Description
– Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive P2X1Rs and P2X3Rs, with IC50s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively[1]. Aurintricarboxylic acid is a potent anti-influenza agent by directly inhibiting the neuraminidase[2]. Aurintricarboxylic acid is an inhibitor of topoisomerase II and apoptosis[3]. Aurintricarboxylic acid is a selective inhibitor of the TWEAK-Fn14 signaling pathway[4]. Aurintricarboxylic acid also acts as a cystathionine-lyase (CSE) inhibitor with an IC50 of 0.6 μM[5]. Aurintricarboxylic acid is a modifier of miRNAs that regulate miRNA function, with an IC50 of 0.47 µM[6].
Web ID
– HY-122575
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C22H14O9
References
– [1]Obrecht AS, et al. Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors. Neuropharmacology. 2019 Nov 1;158:107749.|[2]Hashem AM, et al. Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases. PLoS One. 2009 Dec 17;4(12):e8350.|[3]Benchokroun Y, et al. Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Biochem Pharmacol. 1995 Jan 31;49(3):305-13.|[4]Alison Roos, et al. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells. Oncotarget. 2017 Feb 14; 8(7): 12234–12246.|[5]Youtian Hu, et al. Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase. J Med Chem. 2019 Feb 14;62(3):1677-1683.|[6]Rengen Fan, et al. Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics. RNA Biol. 2019 Jun; 16(6): 707-718.
CAS Number
– 4431-00-9
Molecular Weight
– 422.34
Compound Purity
– 92.0
SMILES
– O=C(C=C/1)C(C(O)=O)=CC1=C(C2=CC(C(O)=O)=C(O)C=C2)C3=CC(C(O)=O)=C(O)C=C3
Clinical Information
– No Development Reported
Research Area
– Infection; Inflammation/Immunology; Neurological Disease
Solubility
– DMSO : 125 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic)|NH4OH : 10 mg/mL (ultrasonic)
Target
– Apoptosis;Influenza Virus;MicroRNA;P2X Receptor;Topoisomerase
Isoform
– P2X1 Receptor;P2X3 Receptor;Topo II
Pathway
– Anti-infection;Apoptosis;Cell Cycle/DNA Damage;Epigenetics;Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
